1 / 23

Why did Science rank immunotherapy as #1?

Why did Science rank immunotherapy as #1?. !!!. Specific immunotherapy Active immunotherapy Antibody therapy Adoptive transfer of T cells Vaccine-based immunotherapy Tumour-based vaccines Virus-based vaccines Peptide-based vaccines others. Immunotherapy.

gareth
Download Presentation

Why did Science rank immunotherapy as #1?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Why did Science rank immunotherapy as #1? !!!

  2. Specific immunotherapy Active immunotherapy Antibody therapy Adoptive transfer of T cells Vaccine-based immunotherapy Tumour-based vaccines Virus-based vaccines Peptide-based vaccines others Immunotherapy

  3. Abridged history of cancer immunotherapy Lesterhuis et al, Nature Reviews 2011 2011: Ipiliumumab shows overall survival benefit in melanoma (2011) 2012-2013: PD1 and PD-L1 blockade has benefit in melanoma, NSCLC, renal cell (4 NEJM papers) 2011-2013: CAR-modified T cells show durable remissions in B cell ALL and CLL

  4. Can we combine local RT, antibodies to oncogenic receptors , selected chemo, hormones to alter tumor microenvironment that allow immunotherapy to optimize host immune response for tumor regression? Major barriers in immunotherapy • Difficult to break tolerance • Poor recruitment to tumor site • Strong suppressive environment within the tumor site • Fast growing tumor in mouse model • Lack of defined antigens and adjuvant for CTL

  5. T cell based therapy

  6. Human CD19 expression by hematopoietic cells within the spleen and lymphoid tissues Tedder, T. F. (2009) CD19: a promising B cell target for rheumatoid arthritis Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2009.184

  7. Using CAR to Overcome Tolerance Creation of Bi-specific T cells TCR heterodimer approach “CAR” or T body approach TCR Chimeric Protein - off the shelf - MHC independent   Tumor binding domain CD3 Extracellular Intracellular Signaling domain        - ITAM

  8. Design of CART19: Choice of 4-1BB Signaling Domain Promotes CAR T Cell Proliferation/Survival

  9. New strategies that target tumor microenvironment and generate local and systemic immune protection

  10. TUMOR Lead Cover Lead Cover Lead Cover Improved Targeting of X-rays tumor Lead Plate X-ray Transparent Plexiglass X-Rays 11 Backscatter Lead Cover

  11. Nude Wt 7500 6000 Control Control 6000 RT RT 4000 4500 Tumor volume (mm3) Tumor volume (mm3) 3000 2000 1500 0 0 0 10 20 30 40 0 10 20 30 40 Days post RT Days post RT *** Local Ablative RT mediates tumor regression B16-SIY: 20Gy or B16: 20Gy x 2 die RT-mediated tumor regression depends on T cells Traditional low dose and hyper-fractionated RT can not control tumor Cure all die Blood 2009, Cancer Res. 2011, JI 2013, JCI in press

  12. 100 Control 75 a RT+ CD8 Percent survival RT 50 25 0 0 10 20 30 40 50 60 70 Days post tumor injection Which immune cells controls tumor growth CD8+ T cells are required for therapeutic response to RTIncrease of PDL-1 induces resistance and allows relapse B16 RT on day 14: 15Gy x day 14, 15, ad 16 2000 *** ) 3 Control 1500 a RT+ CD8 RT 1000 Tumor volume (mm 500 ** 0 0 3 6 9 12 15 Days post RT

  13. 25000 *** 20000 cpm 15000 10000 5000 0 RT-DC+T RT-DC only No RT-DC+T No RT-DC only Which cytokines? can RT increase cross-priming of tumor Ag by intratumor DCs? B16-SIY 20 Gy 14 days 3 days CD11c+ from tumor 2C T cells Proliferation Assay

  14. Why is cross-priming increased • It is known that IFNs can be induced by viral DNA for cross priming of CTL. • Hypothesis: RT-induce DNA damage leads to excessive DNA fragments, like viral infection, which trigger IFNs that induce DC maturation and cross priming • RT induces IFN inside tumor tissues

  15. 5000 IFNAR KO Control ) IFNAR KO RT 3 4000 WT Control WT RT 3000 Tumor Volume (mm 2000 1000 ** 0 0 5 10 15 Days post RT The therapeutic response to RT is dependent on type I IFNs RT induced tumor regression depends on STING but not MyD88 and TRIF While anti-Her2/neu uses MyD88.

  16. RT and anti-PD-L1 reduces MDSC through CTL harvest A Ctrl RT+αPD-L1 RT+αPD-L1+αCD8 19.9% 0.55% 10.2% Gr-1 CD11b Re-activated CTL kills Ag+ cells Including MDSC and tumor B RT TUMOR αB7-H1 mAb (but not anti-PD-1) Day 0 14 17 20

  17. anti-HER2/neu antibody reduces tumor burden: how? Oncogenic blockade FcR mediated kill? NK TUMOR TUMOR

  18. WT mIgG Wt -neu Rag-/- mIgG Rag-/--neu Tumor model that depends on oncogenic signals and FcR dependent in immunocompetent host 1250 TUBO derived from MMTV-Rat neu Tg FcR and NK dep. 1000 750 Tumor volume (mm3) 500 ** Rag-1 +Ab Wt + Ab 250 * 0 0 10 20 30 40 50 Days after tumor inoculation Are T cells essential for Ab-mediated tumor regression? Cancer Cell, 2010

  19. Ab-mediated tumor regression is CD8 dependent: wt and Tg mice A) B) Ctrl Ctrl -neu -neu Neu Tg mice -neu + -CD8 -neu + -CD8 Tumor volume(mm3) Tumor volume(mm3) ** * * Naive 2000 -neu 1500 Days after tumor inoculation Days after tumor inoculation 1250 1000 700 1000 1250 600 C) D) 500 750 500 1000 ** Ctrl 400 0 500 750 -neu 3T3 KB TUBO 300 250 IFN + reactive cells / 106 splenocytes 200 500 memory Tumor volume (mm3) 100 0 250 0 10 20 30 40 50 0 0 10 20 30 40 50 60 0 0 10 20 30 40 50 60 70 80 Days after tumor re-challenge Cancer Cell, 2010, MT, 2013, CCR 2013

  20. How can antibody trigger immune responses? CD8 IFN cytokines Increased Cross-priming ADCC Stress protein or DNA TLRs? MyD88

  21. Type I interferons are induced and necessary during antibody-mediated tumor regression. A TUBO Ab or adenovirus-IFN * WT mice * 0 1 2 3 4 5 6 wk B Ab can induce IFN for tumor regression but antibody can not induce IFN in Ab-resistant tumor Could exogenous IFN be potent for targeting tumor? *

  22. How to target tumor with IFN: armed Ab with IFN for Ab-resistant tumor B16-EGFR 25ug Ab or Ab-IFN WT mice 0 1 2 3 4 5 6 wk Anti-EGFR Linker IFNb Anti-EGFR-IFNb is effective for controlling Ab resistant tumor

More Related